Journal article

Four-repeat tauopathies

Thomas W Roesler, Amir Tayaranian Marvian, Matthias Brendel, Niko-Petteri Nykaenen, Matthias Hoellerhage, Sigrid C Schwarz, Franziska Hopfner, Thomas Koeglsperger, Gesine Respondek, Kerstin Schweyer, Johannes Levin, Victor L Villemagne, Henryk Barthel, Osama Sabri, Ulrich Mueller, Wassilios G Meissner, Gabor G Kovacs, Gunter U Hoeglinger

Progress in Neurobiology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2019

Abstract

Tau is a microtubule-associated protein with versatile functions in the dynamic assembly of the neuronal cytoskeleton. Four-repeat (4R-) tauopathies are a group of neurodegenerative diseases defined by cytoplasmic inclusions predominantly composed of tau protein isoforms with four microtubule-binding domains. Progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease or glial globular tauopathy belong to the group of 4R-tauopathies. The present review provides an introduction in the current concept of 4R-tauopathies, including an overview of the neuropathological and clinical spectrum of these diseases. It describes the genetic and environmental etiological factors..

View full abstract

University of Melbourne Researchers

Grants

Awarded by German Federal Ministry of Education and Research


Awarded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy


Awarded by DFG


Awarded by EU/EFPIA/Innovative Medicines Initiative [2] Joint Undertaking (IMPRIND grant)


Funding Acknowledgements

Gunter U. Hoglinger was supported by the German Federal Ministry of Education and Research (BMBF: 01KU1403A EpiPD; 01EK1605A HitTau), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy ID 390857198), DFG grants (HO2402/6-2, HO2402/18-1MSAomics), the NOMIS foundation (FTLD project), and the EU/EFPIA/Innovative Medicines Initiative [2] Joint Undertaking (IMPRIND grant no 116060). We thank Nuno Mendoca (AbbVie), Tim Buchanan (UCB), Petr Novac (Axon Neuroscience), Dirk Beher (Asceneuron) and Tien Dam (Biogen) for providing latest updates on clinical development of AADvac1, ABBV-8E12, ASN-120290, and UCB0107 therapies.